Integrative molecular concept modeling of prostate cancer progression

Despite efforts to profile prostate cancer, the genetic alterations and biological processes that correlate with the observed histological progression are unclear. Using laser-capture microdissection to isolate 101 cell populations, we have profiled prostate cancer progression from benign epithelium to metastatic disease. By analyzing expression signatures in the context of over 14,000 'molecular concepts', or sets of biologically connected genes, we generated an integrative model of progression. Molecular concepts that demarcate critical transitions in progression include protein biosynthesis, E26 transformation-specific (ETS) family transcriptional targets, androgen signaling and cell proliferation. Of note, relative to low-grade prostate cancer (Gleason pattern 3), high-grade cancer (Gleason pattern 4) shows an attenuated androgen signaling signature, similar to metastatic prostate cancer, which may reflect dedifferentiation and explain the clinical association of grade with prognosis. Taken together, these data show that analyzing gene expression signatures in the context of a compendium of molecular concepts is useful in understanding cancer biology.

[1]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[2]  Nature Genetics , 1991, Nature.

[3]  J. Goméz,et al.  Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study. , 1996, The American journal of surgical pathology.

[4]  T. Visakorpi,et al.  Genetic alterations in hormone-refractory recurrent prostate carcinomas. , 1998, The American journal of pathology.

[5]  L. Hood,et al.  Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. , 1999, Cancer research.

[6]  D. Bostwick,et al.  Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. , 1999, Journal of the National Cancer Institute.

[7]  J. Epstein,et al.  Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. , 1999, The American journal of pathology.

[8]  J. Welsh,et al.  Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. , 2001, Cancer research.

[9]  S. Dhanasekaran,et al.  Delineation of prognostic biomarkers in prostate cancer , 2001, Nature.

[10]  D. Feldman,et al.  The development of androgen-independent prostate cancer , 2001, Nature Reviews Cancer.

[11]  K. Mikoshiba,et al.  Physical and Functional Interactions between Zic and Gli Proteins* , 2001, The Journal of Biological Chemistry.

[12]  E. Lander,et al.  Gene expression correlates of clinical prostate cancer behavior. , 2002, Cancer cell.

[13]  M. Daly,et al.  PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.

[14]  J. Cheville,et al.  Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. , 2003, Cancer research.

[15]  Yingdong Zhao,et al.  Molecular Differentiation of High- and Moderate-Grade Human Prostate Cancer by cDNA Microarray Analysis , 2003, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[16]  P. Pandolfi,et al.  Does the ribosome translate cancer? , 2003, Nature Reviews Cancer.

[17]  Eric C. Griffith,et al.  The Many Forks in FOXO's Road , 2003, Science's STKE.

[18]  W. Isaacs,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group. Pathological and Molecular Aspects of Prostate Cancer Prostate Cancer Ii , 2022 .

[19]  John D. Storey,et al.  Statistical significance for genomewide studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[20]  W. Gerald,et al.  Gene expression profiling predicts clinical outcome of prostate cancer. , 2004, The Journal of clinical investigation.

[21]  Theodore L DeWeese,et al.  Pathological and molecular mechanisms of prostate carcinogenesis: Implications for diagnosis, detection, prevention, and treatment , 2004, Journal of cellular biochemistry.

[22]  Zhong Jiang,et al.  Molecular aspects of diagnostic nucleolar and nuclear envelope changes in prostate cancer , 2004, Journal of cellular biochemistry.

[23]  P. Nelson,et al.  Predicting prostate cancer behavior using transcript profiles. , 2004, The Journal of urology.

[24]  R. Vessella,et al.  Molecular determinants of resistance to antiandrogen therapy , 2004, Nature Medicine.

[25]  Yusuke Nakamura,et al.  Molecular Features of the Transition from Prostatic Intraepithelial Neoplasia (PIN) to Prostate Cancer , 2004, Cancer Research.

[26]  M. Georgescu,et al.  Synergy in tumor suppression by direct interaction of neutral endopeptidase with PTEN. , 2004, Cancer cell.

[27]  J. Wang-Rodriguez,et al.  In silico dissection of cell-type-associated patterns of gene expression in prostate cancer. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[28]  P. Brown,et al.  Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[29]  R. Tibshirani,et al.  Gene expression profiling identifies clinically relevant subtypes of prostate cancer. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[30]  P. Humphrey,et al.  Gleason grading and prognostic factors in carcinoma of the prostate , 2004, Modern Pathology.

[31]  Jane Fridlyand,et al.  Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. , 2005, Human molecular genetics.

[32]  D. Koller,et al.  A module map showing conditional activity of expression modules in cancer , 2004, Nature Genetics.

[33]  T. Barrette,et al.  ONCOMINE: a cancer microarray database and integrated data-mining platform. , 2004, Neoplasia.

[34]  J. Tchinda,et al.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.

[35]  T. Barrette,et al.  Mining for regulatory programs in the cancer transcriptome , 2005, Nature Genetics.

[36]  R. Sutherland,et al.  Molecular markers of prostate cancer outcome. , 2005, European journal of cancer.

[37]  A. Jemal,et al.  Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.

[38]  Christian Pilarsky,et al.  Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival , 2005, The Journal of pathology.

[39]  A. Chinnaiyan,et al.  Integrative analysis of the cancer transcriptome , 2005, Nature Genetics.

[40]  P. Nelson,et al.  Loss of stearoyl‐CoA desaturase expression is a frequent event in prostate carcinoma , 2005, International journal of cancer.

[41]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[42]  John T. Wei,et al.  Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. , 2005, Cancer cell.

[43]  O. Sheils,et al.  Molecular pathology of prostate cancer , 2005, Journal of Clinical Pathology.

[44]  G. Jenster,et al.  Evolution of the androgen receptor pathway during progression of prostate cancer. , 2006, Cancer research.

[45]  Leroy Hood,et al.  A molecular correlate to the Gleason grading system for prostate adenocarcinoma. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[46]  Jason A. Koutcher,et al.  Identification of a tumour suppressor network opposing nuclear Akt function , 2006, Nature.

[47]  M. Rubin,et al.  Integrative biology of prostate cancer progression. , 2006, Annual review of pathology.

[48]  Arul M Chinnaiyan,et al.  TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. , 2006, Cancer research.

[49]  Vladimir Makarov,et al.  Whole transcriptome amplification for gene expression profiling and development of molecular archives. , 2006, Neoplasia.

[50]  T. Golub,et al.  Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. , 2006, Cancer research.